PMA Supplement Types
FDA's five-way taxonomy for post-approval PMA changes, Panel-Track, 180-Day, Real-Time, Special, and 30-Day Notice, each with distinct content and timing.
Definition
After PMA approval, manufacturers must submit a PMA Supplement for most changes to the device, manufacturing, or labeling. FDA recognizes five supplement types: (1) Panel-Track Supplement for significant changes affecting safety or effectiveness, with a new clinical or expert panel review; (2) 180-Day Supplement for major changes evaluated within a 180-day review goal; (3) Real-Time Supplement for minor changes reviewed in a scheduled meeting; (4) Special PMA Supplement (Changes Being Effected) for specific manufacturing or labeling changes that can be implemented while FDA reviews; (5) 30-Day Notice for manufacturing process changes meeting predefined criteria.What this means in practice
Choosing the right supplement type is one of the highest-leverage regulatory decisions for a PMA device. A Panel-Track supplement may take 12-18 months; a 30-Day Notice clears in 30 days if criteria are met. The 30-Day Notice pathway in particular is powerful for manufacturing optimization but is gated by very specific eligibility criteria. The annual PMA report (separate from supplements) covers minor changes that don't require any supplement.- •Defaulting to a 180-Day Supplement when a 30-Day Notice would suffice, wastes 5 months unnecessarily.
- •Treating Special PMA Supplements (CBE) as universally applicable, they are restricted to specific change types defined in 21 CFR 814.39(d).
- •Letting changes accumulate into an annual report when individually they crossed the supplement threshold.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsPMA submission strategy where a manufacturer submits portions of the PMA (modules) sequentially as they become ready, rather than as a single complete application.
FDA's most stringent device marketing application, required for high-risk Class III devices.
Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time.
Yearly report required for Class III PMA devices summarizing changes, complaints, and post-approval study status.
More in Regulatory
· Same categoryFDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Where this term appears across MedTech Terms.
Primary references
3 sources- 1
21 CFR 814.39 - PMA SupplementsVerifiedeCFRecfr.gov
- 2
Modifications to Devices Subject to PMA GuidanceVerifiedFDAfda.gov
- 3
IMDRF DocumentsVerifiedIMDRFimdrf.org
Inline markers like [1] jump to the matching reference above.